Clinical Trial Update: Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) [Phase 2]

View source ↗

Summary

Phase 2 Imperial College London study evaluating dual mTORC1/2 inhibition in advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Ovarian Carcinosarcoma
• Ovarian Clear Cell Adenocarcinoma
• Ovarian Endometrioid Adenocarcinoma
• Ovarian Serous Adenocarcinoma
• Peritoneal Cancer
• Peritoneal Serous Adenocarcinoma

Drugs mentioned

• Vistusertib (AZD2014) (vistusertib)

Snippet

Sponsor: Imperial College London | Conditions: Ovarian Cancer, Ovarian Neoplasms | Phase 2 | Status: COMPLETED